13G Filing: Great Point Partners and Newlink Genetics Corp (NLNK)

Page 7 of 10

Page 7 of 10 – SEC Filing

CUSIP
No.  651511107
13G Page
7 of 9 Pages
(iii) Sole power to
dispose or to direct the disposition of:  0
(iv) Shared power to dispose or to direct the disposition of:  1,500,000
2. Dr. Jeffrey R. Jay, M.D.
(a) Amount beneficially owned:  1,500,000
(b) Percent
of class:  5.13%1
(c) Number of shares as to which the person has:
(i) Sole power to
vote or to direct the vote:  0
(ii) Shared power to vote or to direct the vote:  1,500,000
(iii) Sole power to dispose or to direct the disposition of:  0
(iv) Shared power to dispose or to direct the disposition of:  1,500,000
3. Mr. David Kroin
(a) Amount beneficially owned:  1,500,000
(b) Percent
of class:  5.13%1
(c) Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:  0
(ii) Shared power to vote or to direct the vote:  1,500,000
(iii) Sole power to
dispose or to direct the disposition of:  0
(iv) Shared power to dispose or to direct the disposition of:  1,500,000
Item 5. Ownership of Five Percent or Less of a Class

If this statement is
being filed to report the fact that as of the date hereof each of the Reporting Persons has ceased to be the beneficial owner of
more than five percent of the class of securities, check the following o.

Item 6. Ownership of More than Five Percent on Behalf of Another Person:

See Item 4.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company

Not Applicable.

Item 8. Identification and Classification of Members of the Group

Not Applicable.

Item 9. Notice of Dissolution of Group

Follow Lumos Pharma Inc. (NASDAQ:(LUMO))

Page 7 of 10